Accelevir

Accelevir is a Maryland-based biotechnology company and CLIA-certified central lab providing integrated end-to-end molecular, cellular, and immunological functional capabilities for clinical trials and drug development.

Core Capabilities

• Precision Molecular Analytics: Ultra-sensitive qPCR, digital PCR (dPCR), and targeted short- and long-read sequencing with low input and scarce sample handling.
• Custom Immunology & Flow Cytometry: Bespoke flow cytometry, cytokine profiling, ELISpot, and cell-mediated cytotoxicity assays with deep immune phenotyping.
• Functional Virology: HIV phenotyping, bulk outgrowth, plaque assays, focus-forming assays, and neutralization titer assays.
• Cell Therapy & Gene Editing Services: Vector copy number analysis, integration site analysis, and on/off-target CRISPR editing assessment.
• Integrated Virology-Immunology Workflows: Simultaneous viral load, vector, and immune response measurements from single samples.
• PBMC Processing & Functional Validation: Standardized protocols assessing viability, recovery, and immune performance.
• Vector Biodistribution & Shedding Analysis: Specialized characterization for gene therapy programs.

Therapeutic Focus

Specialized analytics and assay solutions for Infectious Diseases, Cell and Gene Therapies, Oncology, and Inflammatory Diseases. Strong scientific partnerships within the HIV-1 cure community and Johns Hopkins University collaborations.

Regulatory & Operations

CLIA-certified workflow with BSL-2+ facility. Driven by scientific ethos with continual advancement of operational standards.